Sun Pharmaceutical Industries on Monday said it has launched its global innovative drug ILUMYA in India for the treatment of ...

Sun Pharma launches Ilumya (Tildrakizumab) in India, expanding its specialty medicines portfolio and bringing advanced ...

Stay informed with the Sun Pharma Stock Liveblog, your comprehensive resource for real-time updates and in-depth analysis of ...

Brokerages like Citi and Choice Institutional Equities are optimistic about the pharmaceutical and flexible workspace sectors ...

Sun Pharma has launched an eye-opening awareness push about a common—and commonly overlooked—complication of diabetes. | Sun Pharma has launched an eye-opening awareness push about a common—and ...

Track TCS, Sun Pharma, and sector leaders as Nifty eyes higher targets; spot key stocks for your Monday investment moves now.

Morgan Stanley maintained its Overweight rating on Sun Pharma. The brokerage has set a target price of Rs 2,026, indicating a ...

A former sales representative for Sun Pharmaceuticals filed a retaliation lawsuit against the drugmaker, claiming he was fired for complaining about its marketing tactics, according to STAT news. 1.

Former Sun Pharmaceuticals sales representative Jeannine Umpleby filed a retaliation lawsuit against the drugmaker, claiming she was fired for complaining that a district manager improperly ...

Important regulatory news last week included Otsuka gaining accelerated Food and Drug Administration approval for its Voyxact (sibeprenlimab) for immunoglobulin A nephrology, India’s Sun Pharma for ...

Sun Pharma introduces ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis treatment. A novel biologic with proven efficacy.